Clinical Trial Update: A Study to Test Different Doses of BI 3011441 in Japanese People With Different Types of Advanced Cancer (NRAS/KRAS Mutation Positive) [Phase 1]

View source ↗

Summary

A Phase 1 dose-escalation study of BI 3011441 in Japanese patients with NRAS- or KRAS-mutant advanced solid tumors has completed and posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kras-mutant Cancer
• Solid Tumors

Drugs mentioned

• BI 3011441

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Solid Tumors, KRAS Mutation | Phase 1 | Status: COMPLETED | Results posted: 2024-09-19